Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foscan PDT in inoperable bile duct cancers
NCT03003065Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2014
- Primary completion
- Apr 2023
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temoporfin in cholangiocarcinoma (CCA), sponsored by The Chinese University of Hong Kong. Primary endpoint: Safety graded by CTCAE version 3.0 at 10 years. Started Mar 2014; status: completed.
02
Drugs
temoporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03003065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003065.